For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
3
views
188
references
 Top references
cited by
9
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      336
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      PET molecular imaging for pathophysiological visualization in Alzheimer’s disease

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Alzheimer’s disease (AD) is the most common dementia worldwide. The exact etiology of AD is unclear as yet, and no effective treatments are currently available, making AD a tremendous burden posed on the whole society. As AD is a multifaceted and heterogeneous disease, and most biomarkers are dynamic in the course of AD, a range of biomarkers should be established to evaluate the severity and prognosis. Positron emission tomography (PET) offers a great opportunity to visualize AD from diverse perspectives by using radiolabeled agents involved in various pathophysiological processes; PET imaging technique helps to explore the pathomechanisms of AD comprehensively and find out the most appropriate biomarker in each AD phase, leading to a better evaluation of the disease. In this review, we discuss the application of PET in the course of AD and summarized radiolabeled compounds with favorable imaging characteristics.

          Related collections

          Most cited references188

          • Record: found
          • Abstract: found
          • Article: found

          The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

          Guy M McKhann, David S. Knopman, Howard Chertkow … (2011)
          The National Institute on Aging and the Alzheimer's Association charged a workgroup with the task of revising the 1984 criteria for Alzheimer's disease (AD) dementia. The workgroup sought to ensure that the revised criteria would be flexible enough to be used by both general healthcare providers without access to neuropsychological testing, advanced imaging, and cerebrospinal fluid measures, and specialized investigators involved in research or in clinical trial studies who would have these tools available. We present criteria for all-cause dementia and for AD dementia. We retained the general framework of probable AD dementia from the 1984 criteria. On the basis of the past 27 years of experience, we made several changes in the clinical criteria for the diagnosis. We also retained the term possible AD dementia, but redefined it in a manner more focused than before. Biomarker evidence was also integrated into the diagnostic formulations for probable and possible AD dementia for use in research settings. The core clinical criteria for AD dementia will continue to be the cornerstone of the diagnosis in clinical practice, but biomarker evidence is expected to enhance the pathophysiological specificity of the diagnosis of AD dementia. Much work lies ahead for validating the biomarker diagnosis of AD dementia. Copyright © 2011. Published by Elsevier Inc.
          Article 0 comments Cited 2981 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

            Marilyn Albert, Steven Dekosky, Dennis D Dickson … (2011)
            The National Institute on Aging and the Alzheimer's Association charged a workgroup with the task of developing criteria for the symptomatic predementia phase of Alzheimer's disease (AD), referred to in this article as mild cognitive impairment due to AD. The workgroup developed the following two sets of criteria: (1) core clinical criteria that could be used by healthcare providers without access to advanced imaging techniques or cerebrospinal fluid analysis, and (2) research criteria that could be used in clinical research settings, including clinical trials. The second set of criteria incorporate the use of biomarkers based on imaging and cerebrospinal fluid measures. The final set of criteria for mild cognitive impairment due to AD has four levels of certainty, depending on the presence and nature of the biomarker findings. Considerable work is needed to validate the criteria that use biomarkers and to standardize biomarker analysis for use in community settings. Copyright © 2011 The Alzheimer's Association. All rights reserved.
            Article 0 comments Cited 1887 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

              G. McKhann, D. Drachman, M. Folstein … (1984)
              Neurology, 34(7), 939-939
              Article 0 comments Cited 1539 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Contributors
                Jing Wang: wangjing5678@zju.edu.cn
                Hyeon Jeong Lee: hjlee@zju.edu.cn
                Hong Zhang:
                ORCID: http://orcid.org/0000-0002-4084-5150
                hzhang21@zju.edu.cn
                Journal
                Journal ID (nlm-ta): Eur J Nucl Med Mol Imaging
                Journal ID (iso-abbrev): Eur J Nucl Med Mol Imaging
                Title: European Journal of Nuclear Medicine and Molecular Imaging
                Publisher: Springer Berlin Heidelberg (Berlin/Heidelberg )
                ISSN (Print): 1619-7070
                ISSN (Electronic): 1619-7089
                Publication date (Electronic): 14 November 2022
                Publication date PMC-release: 14 November 2022
                Publication date (Print): 2023
                Volume: 50
                Issue: 3
                Pages: 765-783
                Affiliations
                [1 ]GRID grid.412465.0, Department of Nuclear Medicine and PET Center, , The Second Affiliated Hospital of Zhejiang University School of Medicine, ; 88 Jiefang Road, Hangzhou, 310009 Zhejiang China
                [2 ]GRID grid.13402.34, ISNI 0000 0004 1759 700X, Institute of Nuclear Medicine and Molecular Imaging of Zhejiang University, ; Hangzhou, 310009 Zhejiang China
                [3 ]Key Laboratory of Medical Molecular Imaging of Zhejiang Province, Hangzhou, 310009 Zhejiang China
                [4 ]GRID grid.13402.34, ISNI 0000 0004 1759 700X, College of Biomedical Engineering and Instrument Science, , Zhejiang University, ; Hangzhou, 310014 Zhejiang China
                [5 ]GRID grid.13402.34, ISNI 0000 0004 1759 700X, Key Laboratory for Biomedical Engineering of Ministry of Education, , Zhejiang University, ; Hangzhou, 310014 Zhejiang China
                Author information
                http://orcid.org/0000-0002-4084-5150
                Article
                Publisher ID: 5999
                DOI: 10.1007/s00259-022-05999-z
                PMC ID: 9852140
                PubMed ID: 36372804
                SO-VID: 8f2b4831-cd67-407b-8b9e-7684f547d6f7
                Copyright © © The Author(s) 2022
                License:

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                Date received : 27 July 2022
                Date accepted : 9 October 2022
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/100014717, National Outstanding Youth Science Fund Project of National Natural Science Foundation of China;
                Award ID: 81725009
                Award Recipient :
                Categories
                Subject: Review Article
                Custom metadata
                issue-copyright-statement © Springer-Verlag GmbH Germany, part of Springer Nature 2023

                ScienceOpen disciplines: Radiology & Imaging
                Keywords: alzheimer’s disease,positron emission tomography (pet),molecular imaging
                Data availability:
                ScienceOpen disciplines: Radiology & Imaging
                Keywords: alzheimer’s disease, positron emission tomography (pet), molecular imaging

                Comments

                Comment on this article

                scite_

                Similar content336

                See all similar

                Cited by9

                See all cited by

                Most referenced authors4,269

                See all reference authors